109 related articles for article (PubMed ID: 38733180)
1. [Current status and challenges of clinical research and development of new drugs for liver diseases].
Shen ZY; Cai XB; Lu LG
Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):289-294. PubMed ID: 38733180
[TBL] [Abstract][Full Text] [Related]
2. Analysis of Clinical Trials of New Drugs for Liver Diseases in China.
Lin L; Li H
Drug Des Devel Ther; 2021; 15():3181-3191. PubMed ID: 34321867
[TBL] [Abstract][Full Text] [Related]
3. Current status in the therapy of liver diseases.
Uhl P; Fricker G; Haberkorn U; Mier W
Int J Mol Sci; 2014 Apr; 15(5):7500-12. PubMed ID: 24786290
[TBL] [Abstract][Full Text] [Related]
4. A report from The Liver Meeting 2014 (November 7-11 - Boston, Massachusetts, USA).
Rabasseda X
Drugs Today (Barc); 2014 Nov; 50(11):763-74. PubMed ID: 25525637
[TBL] [Abstract][Full Text] [Related]
5. [Challenges and optimization strategies for clinical research and the development of new drugs for liver fibrosis].
Cai XB; Qu Y; Lu LG
Zhonghua Gan Zang Bing Za Zhi; 2024 Apr; 32(4):303-305. PubMed ID: 38733183
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases.
Mallat A; Teixeira-Clerc F; Deveaux V; Lotersztajn S
Expert Opin Ther Targets; 2007 Mar; 11(3):403-9. PubMed ID: 17298297
[TBL] [Abstract][Full Text] [Related]
7. A report from the European Association for the Study of the Liver's 50th International Liver Congress (April 22-26 - Vienna, Austria).
Rabasseda X
Drugs Today (Barc); 2015 Apr; 51(4):261-71. PubMed ID: 26020068
[TBL] [Abstract][Full Text] [Related]
8. [Silymarin in the treatment of chronic liver diseases: past and future].
Fehér J; Lengyel G
Orv Hetil; 2008 Dec; 149(51):2413-8. PubMed ID: 19073452
[TBL] [Abstract][Full Text] [Related]
9. Albumin-drug conjugates in the treatment of hepatic disorders.
Fiume L; Manerba M; Di Stefano G
Expert Opin Drug Deliv; 2014 Aug; 11(8):1203-17. PubMed ID: 24773257
[TBL] [Abstract][Full Text] [Related]
10. Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects.
Vargas JI; Arrese M; Shah VH; Arab JP
Curr Gastroenterol Rep; 2017 Sep; 19(9):43. PubMed ID: 28752475
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Wnt signaling pathway: the challenge of reducing scarring without affecting repair.
Jarman EJ; Boulter L
Expert Opin Investig Drugs; 2020 Feb; 29(2):179-190. PubMed ID: 31948298
[No Abstract] [Full Text] [Related]
12. Insight into the role of TRAIL in liver diseases.
Jiang W; Wu DB; Fu SY; Chen EQ; Tang H; Zhou TY
Biomed Pharmacother; 2019 Feb; 110():641-645. PubMed ID: 30544063
[TBL] [Abstract][Full Text] [Related]
13. [Long-term therapy of liver diseases].
Markoff N
Wien Med Wochenschr; 1972 Feb; 122(7):95-9. PubMed ID: 4621921
[No Abstract] [Full Text] [Related]
14. New Therapies, Evidence, and Guidance in Hepatitis C Management: Expert Practices and Insights from an Educational Symposium at the AMCP 27th Annual Meeting Expo.
Terrault N; Monto A; Stinchon MR; Rusie E; Moreo K
J Manag Care Spec Pharm; 2015 Sep; 21(9):S1-14. PubMed ID: 26308363
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.
Janczewska E; Kołek MF; Lorenc B; Klapaczyński J; Tudrujek-Zdunek M; Sitko M; Mazur W; Zarębska-Michaluk D; Buczyńska I; Dybowska D; Czauż-Andrzejuk A; Berak H; Krygier R; Jaroszewicz J; Citko J; Piekarska A; Dobracka B; Socha Ł; Deroń Z; Laurans Ł; Białkowska-Warzecha J; Tronina O; Adamek B; Tomasiewicz K; Simon K; Pawłowska M; Halota W; Flisiak R
World J Gastroenterol; 2021 May; 27(18):2177-2192. PubMed ID: 34025072
[TBL] [Abstract][Full Text] [Related]
16. [Progress in diagnosis and treatment of viral hepatitis in children].
Chang YN; Xu HM
Zhonghua Gan Zang Bing Za Zhi; 2021 Jan; 29(1):16-20. PubMed ID: 33541019
[TBL] [Abstract][Full Text] [Related]
17. The role of Andrographolide in the prevention and treatment of liver diseases.
Qin X; Wang X; Tian M; Dong Z; Wang J; Wang C; Huang Q
Phytomedicine; 2023 Jan; 109():154537. PubMed ID: 36610122
[TBL] [Abstract][Full Text] [Related]
18. How effective are nonalcoholic fatty liver disease models for drug discovery?
Hundertmark J; Tacke F
Expert Opin Drug Discov; 2020 Nov; 15(11):1237-1240. PubMed ID: 32524859
[TBL] [Abstract][Full Text] [Related]
19. Emerging drugs for complications of end-stage liver disease.
Dowman JK; Holt AP; Newsome PN; Adams DH
Expert Opin Emerg Drugs; 2008 Mar; 13(1):159-74. PubMed ID: 18321155
[TBL] [Abstract][Full Text] [Related]
20. Sequential drug delivery for liver diseases.
Huang X; Lee F; Teng Y; Lingam CB; Chen Z; Sun M; Song Z; Balachander GM; Leo HL; Guo Q; Shah I; Yu H
Adv Drug Deliv Rev; 2019; 149-150():72-84. PubMed ID: 31734169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
